Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 14, 2022; 28(30): 4201-4210
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4201
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4201
Table 1 Baseline characteristics of the included studies
Ref. | Year | Country | Design | Compared interventions | Number of patients | Male/female ratio | Age in yr, mean | Squamous cell cancer/adenocarcinoma ratio | Inclusion criteria |
Straatman et al[25] | 2012 | Netherlands, Spain, Italy | Multicenter | MI-TT | 59-56 | 43/16-46/17 | 62.3–61.8 | 24/35-19/36 | cT1-3, N0-1, M0 |
van der Sluis et al[26] | 2019 | Netherlands | Single center | RA-TT | 54-55 | 46/8-42/13 | 64-65 | 13/41-12/43 | T1-4a, N0-3, M0 |
Mariette et al[27] | 2019 | France | Multi center | H-TT | 103-104 | 88/15-175/32 | 59-61 (median) | 46/57-84/123 | T1-3, N0-1, M0 |
Guo et al[28] | 2013 | China | Single center | MI-TT | 111-110 | 68/43-72/38 | 57.3-60.8 | No information | T1-3, N0-1, M0 |
Ma et al[29] | 2018 | China | Single center | MI-TT | 47-97 | 36/11-83/14 | 61-59.3 | 43/0-91/2 | Resectable cancer |
Jacobi et al[30] | 1997 | Germany | Single center | TH-TT | 16-16 | No information | 54-55 | 13/3-13/3 | Resectable cancer |
Goldminc et al[31] | 1993 | Australia | Single center | TH-TT | 32-35 | 31/1-33/2 | 57.4-57.4 | 32/0-35/0 | Resectable squamous cell cancer |
Chu et al[32] | 1997 | China | Single center | TH-TT | 20-19 | 18/2-17/2 | 60.7-63.9 | No information | Lower third resectable cancer |
Hulscher et al[33] | 2002 | Netherlands | Multicenter | TH-TT | 106-114 | 92/14-97/17 | 69-64 | 0/106-0/114 | Resectable adenocarcinoma |
Yang et al[35] | 2016 | China | Single center | MI-TT | 120-120 | 82/38-87/33 | 62.5 -67.8 | 75/45-72/48 | T1-3, N0-1, M0 |
Paireder et al[34] | 2018 | Austria | Single center | H-TT | 14-12 | 10/4-10/2 | 64.5-62.5 (median) | 4/10-1/11 | Siewert I-II, resectable squamous cell cancer |
- Citation: Szakó L, Németh D, Farkas N, Kiss S, Dömötör RZ, Engh MA, Hegyi P, Eross B, Papp A. Network meta-analysis of randomized controlled trials on esophagectomies in esophageal cancer: The superiority of minimally invasive surgery. World J Gastroenterol 2022; 28(30): 4201-4210
- URL: https://www.wjgnet.com/1007-9327/full/v28/i30/4201.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i30.4201